<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765998</url>
  </required_header>
  <id_info>
    <org_study_id>18-2012.CTIL</org_study_id>
    <nct_id>NCT01765998</nct_id>
  </id_info>
  <brief_title>The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease)</brief_title>
  <official_title>The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) and Markers of Inflammation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Baruch Padeh Medical Center, Poriya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Baruch Padeh Medical Center, Poriya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inflammatory Bowel Disease (IBD) is an immune mediated chronic intestinal condition. It
      includes ulcerative colitis (UC) and Crohn's disease(CD). probiotics have been shown to be
      effective in varried clinical conditions ranging fron infantile diarrhea, necrotizing
      enterocolitis,helicobacter pylori infections, etc.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective study that will enroll 50 patients with Crohn's disease.Each patient
      will get the study medication for 6 weeks and will be evaluated twice- before enrollment and
      after 6 weeks of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>February 2013</start_date>
  <completion_date type="Anticipated">February 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial stem cells</measure>
    <time_frame>one year</time_frame>
    <description>to study the ability to create endothelial progenitor stem cells following probiotic management compared to placebo group</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>Probiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To study the effect of probiotic on the ability to build endothelial progenitor stem cells and to study clinical recovery of patients with Crohn's Disease.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This will be the comparison group to the experimantal group that recives Probiotic.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic</intervention_name>
    <description>Clinical evaluation according to the Crohn's activity scale</description>
    <arm_group_label>Probiotic</arm_group_label>
    <other_name>Bio 25</other_name>
    <other_name>powder in HPMC Capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with Crohns' disease who are stable or have mild acute exacerbations that do
             not necessitate treatment with systemic corticosteroids

        Exclusion Criteria:

          -  pregnant women, under 18 years or over 60 years,

          -  patients with known ulcerative colitis,

          -  patients with any cancer,

          -  patients with heart failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Blum, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baruch Padeh Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baruch Padeh Medical Center</name>
      <address>
        <city>Tiberias</city>
        <state>Lower galilee</state>
        <zip>15208</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 6, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2013</study_first_posted>
  <last_update_submitted>January 10, 2013</last_update_submitted>
  <last_update_submitted_qc>January 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Baruch Padeh Medical Center, Poriya</investigator_affiliation>
    <investigator_full_name>Arnon Blum</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Crohn's disease, endothelial progenitor cells, probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Disease Progression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

